These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

262 related articles for article (PubMed ID: 30489256)

  • 21. Identification of GDC-0810 (ARN-810), an Orally Bioavailable Selective Estrogen Receptor Degrader (SERD) that Demonstrates Robust Activity in Tamoxifen-Resistant Breast Cancer Xenografts.
    Lai A; Kahraman M; Govek S; Nagasawa J; Bonnefous C; Julien J; Douglas K; Sensintaffar J; Lu N; Lee KJ; Aparicio A; Kaufman J; Qian J; Shao G; Prudente R; Moon MJ; Joseph JD; Darimont B; Brigham D; Grillot K; Heyman R; Rix PJ; Hager JH; Smith ND
    J Med Chem; 2015 Jun; 58(12):4888-904. PubMed ID: 25879485
    [TBL] [Abstract][Full Text] [Related]  

  • 22. The prevalence of estrogen receptor-1 mutation in advanced breast cancer: The estrogen receptor one study (EROS1).
    Najim O; Huizing M; Papadimitriou K; Trinh XB; Pauwels P; Goethals S; Zwaenepoel K; Peterson K; Weyler J; Altintas S; van Dam P; Tjalma W
    Cancer Treat Res Commun; 2019; 19():100123. PubMed ID: 30826563
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Evaluation of the pharmacological activities of RAD1901, a selective estrogen receptor degrader.
    Wardell SE; Nelson ER; Chao CA; Alley HM; McDonnell DP
    Endocr Relat Cancer; 2015 Oct; 22(5):713-24. PubMed ID: 26162914
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Acquired HER2 mutations in ER
    Nayar U; Cohen O; Kapstad C; Cuoco MS; Waks AG; Wander SA; Painter C; Freeman S; Persky NS; Marini L; Helvie K; Oliver N; Rozenblatt-Rosen O; Ma CX; Regev A; Winer EP; Lin NU; Wagle N
    Nat Genet; 2019 Feb; 51(2):207-216. PubMed ID: 30531871
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Antiestrogen Resistant Cell Lines Expressing Estrogen Receptor α Mutations Upregulate the Unfolded Protein Response and are Killed by BHPI.
    Mao C; Livezey M; Kim JE; Shapiro DJ
    Sci Rep; 2016 Oct; 6():34753. PubMed ID: 27713477
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Novel oral selective estrogen receptor degraders (SERDs) to target hormone receptor positive breast cancer: elacestrant as the poster-child.
    Keenan JC; Medford AJ; Dai CS; Wander SA; Spring LM; Bardia A
    Expert Rev Anticancer Ther; 2024 Jun; 24(6):397-405. PubMed ID: 38642015
    [TBL] [Abstract][Full Text] [Related]  

  • 27. G1T48, an oral selective estrogen receptor degrader, and the CDK4/6 inhibitor lerociclib inhibit tumor growth in animal models of endocrine-resistant breast cancer.
    Andreano KJ; Wardell SE; Baker JG; Desautels TK; Baldi R; Chao CA; Heetderks KA; Bae Y; Xiong R; Tonetti DA; Gutgesell LM; Zhao J; Sorrentino JA; Thompson DA; Bisi JE; Strum JC; Thatcher GRJ; Norris JD
    Breast Cancer Res Treat; 2020 Apr; 180(3):635-646. PubMed ID: 32130619
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Bazedoxifene exhibits antiestrogenic activity in animal models of tamoxifen-resistant breast cancer: implications for treatment of advanced disease.
    Wardell SE; Nelson ER; Chao CA; McDonnell DP
    Clin Cancer Res; 2013 May; 19(9):2420-31. PubMed ID: 23536434
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Benzothiophenone Derivatives Targeting Mutant Forms of Estrogen Receptor-α in Hormone-Resistant Breast Cancers.
    Singh K; Munuganti RSN; Lallous N; Dalal K; Yoon JS; Sharma A; Yamazaki T; Cherkasov A; Rennie PS
    Int J Mol Sci; 2018 Feb; 19(2):. PubMed ID: 29462880
    [TBL] [Abstract][Full Text] [Related]  

  • 30. ESR1 mutations affect anti-proliferative responses to tamoxifen through enhanced cross-talk with IGF signaling.
    Gelsomino L; Gu G; Rechoum Y; Beyer AR; Pejerrey SM; Tsimelzon A; Wang T; Huffman K; Ludlow A; Andò S; Fuqua SAW
    Breast Cancer Res Treat; 2016 Jun; 157(2):253-265. PubMed ID: 27178332
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Long Non-Coding RNA H19 Acts as an Estrogen Receptor Modulator that is Required for Endocrine Therapy Resistance in ER+ Breast Cancer Cells.
    Basak P; Chatterjee S; Bhat V; Su A; Jin H; Lee-Wing V; Liu Q; Hu P; Murphy LC; Raouf A
    Cell Physiol Biochem; 2018; 51(4):1518-1532. PubMed ID: 30497079
    [TBL] [Abstract][Full Text] [Related]  

  • 32. AZD9496: An Oral Estrogen Receptor Inhibitor That Blocks the Growth of ER-Positive and ESR1-Mutant Breast Tumors in Preclinical Models.
    Weir HM; Bradbury RH; Lawson M; Rabow AA; Buttar D; Callis RJ; Curwen JO; de Almeida C; Ballard P; Hulse M; Donald CS; Feron LJ; Karoutchi G; MacFaul P; Moss T; Norman RA; Pearson SE; Tonge M; Davies G; Walker GE; Wilson Z; Rowlinson R; Powell S; Sadler C; Richmond G; Ladd B; Pazolli E; Mazzola AM; D'Cruz C; De Savi C
    Cancer Res; 2016 Jun; 76(11):3307-18. PubMed ID: 27020862
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Structure-function relationships of the raloxifene-estrogen receptor-alpha complex for regulating transforming growth factor-alpha expression in breast cancer cells.
    Liu H; Park WC; Bentrem DJ; McKian KP; Reyes Ade L; Loweth JA; Schafer JM; Zapf JW; Jordan VC
    J Biol Chem; 2002 Mar; 277(11):9189-98. PubMed ID: 11751902
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Discovery of 6-(2,4-Dichlorophenyl)-5-[4-[(3
    El-Ahmad Y; Tabart M; Halley F; Certal V; Thompson F; Filoche-Rommé B; Gruss-Leleu F; Muller C; Brollo M; Fabien L; Loyau V; Bertin L; Richepin P; Pilorge F; Desmazeau P; Girardet C; Beccari S; Louboutin A; Lebourg G; Le-Roux J; Terrier C; Vallée F; Steier V; Mathieu M; Rak A; Abecassis PY; Vicat P; Benard T; Bouaboula M; Sun F; Shomali M; Hebert A; Levit M; Cheng H; Courjaud A; Ginesty C; Perrault C; Garcia-Echeverria C; McCort G; Schio L
    J Med Chem; 2020 Jan; 63(2):512-528. PubMed ID: 31721572
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Acquired resistance to selective estrogen receptor modulators (SERMs) in clinical practice (tamoxifen & raloxifene) by selection pressure in breast cancer cell populations.
    Fan P; Craig Jordan V
    Steroids; 2014 Nov; 90():44-52. PubMed ID: 24930824
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Complete elimination of estrogen receptor α by PROTAC estrogen receptor α degrader ERD-148 in breast cancer cells.
    Hu B; Hu J
    Breast Cancer Res Treat; 2024 Jan; 203(2):383-396. PubMed ID: 37847455
    [TBL] [Abstract][Full Text] [Related]  

  • 37. MiRNA-27a sensitizes breast cancer cells to treatment with Selective Estrogen Receptor Modulators.
    Ljepoja B; García-Roman J; Sommer AK; Wagner E; Roidl A
    Breast; 2019 Feb; 43():31-38. PubMed ID: 30415143
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Activating
    Toy W; Weir H; Razavi P; Lawson M; Goeppert AU; Mazzola AM; Smith A; Wilson J; Morrow C; Wong WL; De Stanchina E; Carlson KE; Martin TS; Uddin S; Li Z; Fanning S; Katzenellenbogen JA; Greene G; Baselga J; Chandarlapaty S
    Cancer Discov; 2017 Mar; 7(3):277-287. PubMed ID: 27986707
    [TBL] [Abstract][Full Text] [Related]  

  • 39. ESR1 F404 Mutations and Acquired Resistance to Fulvestrant in ESR1-Mutant Breast Cancer.
    Kingston B; Pearson A; Herrera-Abreu MT; Sim LX; Cutts RJ; Shah H; Moretti L; Kilburn LS; Johnson H; Macpherson IR; Ring A; Bliss JM; Hou Y; Toy W; Katzenellenbogen JA; Chandarlapaty S; Turner NC
    Cancer Discov; 2024 Feb; 14(2):274-289. PubMed ID: 37982575
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Differential biochemical and cellular actions of Premarin estrogens: distinct pharmacology of bazedoxifene-conjugated estrogens combination.
    Berrodin TJ; Chang KC; Komm BS; Freedman LP; Nagpal S
    Mol Endocrinol; 2009 Jan; 23(1):74-85. PubMed ID: 19036900
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 14.